SEC 13F Intelligence

Lion Point Capital, LP / TGTX

Lion Point Capital, LP’s Tg Therapeutics Inc Position

Does Lion Point Capital, LP own Tg Therapeutics Inc (TGTX)? Not currently — the last reported position was 1.16M shares worth $22M in Q4 2021; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$22M
Q4 2021
Shares
1.16M
% of Portfolio
+5.91%
Quarters Held
7
position exited

Position History TGTX

Reported value by quarter
Q2 ’20: $17MQ2 ’20Q3 ’20: $36MQ3 ’20Q4 ’20: $69MQ4 ’20Q1 ’21: $29MQ1 ’21Q2 ’21: $24MQ2 ’21Q3 ’21: $28MQ3 ’21Q4 ’21: $22MQ4 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q4 20211.16M$22M+5.91%
Q3 2021839.1K$28M+5.24%
Q2 2021609.1K$24M+4.08%
Q1 2021609.1K$29M+5.34%
Q4 20201.33M$69M+13.30%
Q3 20201.33M$36M+7.79%
Q2 2020897.8K$17M+4.24%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Lion Point Capital, LP’s full portfolio or all institutional holders of TGTX.